Search results for "Bow"

showing 10 items of 1006 documents

Treatment of irritable bowel syndrome with probiotics. An etiopathogenic approach at last?

2009

Irritable bowel syndrome (IBS) is the most common functional digestive disorder, and may affect 11-20% of the adult population in industrialized countries. In accordance with Rome III criteria (2006) IBS involves abdominal pain and bowel habit disturbance, which are not explained by structural or biochemical abnormalities. Several hypotheses attempt to account for the pathophysiology of IBS, but the etiology still remains uncertain or obscure, perhaps multifactorial. Abnormalities in colonic microflora have recently been suggested in such patients, as has abnormal small-intestine bacterial overgrowth (SIBO), or in particular a significant reduction in the amount of intraluminal Bifidobacter…

MaleAbdominal painFunctional digestive disordersGastroenterologylaw.inventionIrritable Bowel SyndromeProbioticlawPrevalenceIntestinal MucosaIrritable bowel syndromeEnterocolitis PseudomembranousBifidobacteriumEnterocolitisClinical Trials as TopicTravelbiologyGastroenterologyGeneral MedicineIntestinesTreatment OutcomeFemalemedicine.symptomAdultDiarrheamedicine.medical_specialtyfunctional digestive disordersirritable bowel syndrome (ibs)mucosal associated microbiota (mam)Internal medicineDigestive disordermedicineIntestinal microfloraHumanslcsh:RC799-869intestinal microfloraMucosal associated microbiota (MAM)business.industryClostridioides difficileIrritable bowel syndrome (IBS)ProbioticsAbdominal distensionbiology.organism_classificationmedicine.diseaseLactobacillusSpainlcsh:Diseases of the digestive system. GastroenterologyBifidobacteriumFlatulencebusinessRevista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva
researchProduct

Perception of the Role of Food and Dietary Modifications in Patients with Inflammatory Bowel Disease: Impact on Lifestyle

2021

Background: Diet has a relevant role in triggering symptoms in inflammatory bowel disease (IBD) from the patients’ perspective, but there is gap the between patients’ and doctors’ perceptions. Few studies have addressed this topic. The aim of this study was to evaluate food habits and nutrition knowledge in a homogeneous cohort of patients with IBD from southern Italy. Methods: 167 consecutive patients with IBD were recruited. The survey was based on the administration of a semi-structured questionnaire assessing demographics, disease features, dietary behavior, and food intolerance. Results: The majority of patients did not consider food a cause of their disease. However more than 80% chan…

MaleAdultAdolescentfood perceptionmedia_common.quotation_subjectlcsh:TX341-641DiseaseInflammatory bowel diseaseArticleDietary changeYoung Adult03 medical and health sciences0302 clinical medicineCrohn Diseaseinflammatory bowel diseaseSurveys and QuestionnairesPerceptionEnvironmental healthFood choiceHumansSurveys and QuestionnaireMedicineLife Styledietary changesQualitative ResearchAgedmedia_commonNutrition and Dieteticsbusiness.industryFeeding BehaviorMiddle Agedmedicine.diseaseDietFood intoleranceMalnutritionItaly030220 oncology & carcinogenesisCohortPerceptionColitis UlcerativeFemale030211 gastroenterology & hepatologybusinesslcsh:Nutrition. Foods and food supplyPsychosocialHumanFood ScienceNutrients
researchProduct

Cancer in Crohn's Disease patients treated with infliximab: a long-term multicenter matched pair study

2011

Background: The long-term risk of neoplasia in Crohn's disease (CD) patients treated with infliximab is undefined. The aim was to assess, in a multicenter, matched-pair study, whether infliximab use in CD is associated with an increased frequency of neoplasia in the long term. Methods: A multicenter, long-term, matched-pair study was conducted in 12 referral inflammatory bowel disease (IBD) centers. An initial cohort of 808 CD patients, including 404 infliximab-treated (CD-IFX) and 404 matched CD controls never treated with infliximab (CD-C) studied from 1999 to 2004, was followed up for an additional 4 years (2004–2008). Cases and controls were matched for: sex, age (±5 years), CD site, fo…

MaleAdultmedicine.medical_specialtyTime FactorsCROHN'S DISEASECrohn’s disease infliximab cancer matched-pairInflammatory bowel diseaseGastroenterologyAntibodiesCohort StudiesGastrointestinal AgentsCrohn DiseaseInternal medicineNeoplasmsINFLIXIMABMonoclonalmedicineImmunology and AllergyHumanstherapeutic use Case-Control Studies Cohort Studies Crohn Diseaseetiology Survival Rate Time Factors Treatment OutcomeSurvival rateAgedCancer Infliximab Inflammatory bowel diseaseCrohn's diseasebusiness.industryGastroenterologyCase-control studyAntibodies MonoclonalCancerMiddle Ageddrug therapy Female Follow-Up Studies Gastrointestinal Agenttherapeutic use Humans Male Middle Aged Neoplasmmedicine.diseaseTreatment Outcome; Male; Time Factors; Survival Rate; Middle Aged; Female; Neoplasms; Gastrointestinal Agents; Humans; Cohort Studies; Follow-Up Studies; Aged; Adult; Antibodies Monoclonal; Case-Control Studies; Crohn DiseaseCANCERInfliximabSurgerySurvival RateSettore MED/18 - Chirurgia GeneraleTreatment OutcomeCase-Control StudiesCohortFemaleAdult Aged Antibodiebusinessmedicine.drugCohort studyFollow-Up Studies
researchProduct

Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory …

2011

See related article, Oostlander AE et al, on page 116 in Gastroenterology. BACKGROUND & AIMS: Few data are available on effects of biologic therapies in patients more than 65 years old with inflammatory bowel disease (IBD). We evaluated the risk and benefits of therapy with tumor necrosis factor (TNF) inhibitors in these patients. METHODS: We collected data from patients with IBD treated with infliximab (n 2475) and adalimumab (n 604) from 2000 to 2009 at 16 tertiary centers. Ninety-five patients (3%) were more than 65 years old (52 men; 37 with ulcerative colitis and 58 with Crohn’s disease; 78 treated with infliximab and 17 with adalimumab). The control group comprised 190 patients 65 yea…

MaleAgingSettore MED/09 - Medicina InternaBiologicantagonists /&/ inhibitors/immunology Young AdultInflammatory bowel diseaseHumanized AntibodieElderlyNeoplasmsMonoclonalYoung adultAged 80 and overSettore MED/12 - GastroenterologiaCrohn's diseaseGastroenterologyAge FactorsAntibodies MonoclonalMiddle AgedUlcerative colitisepidemiology Opportunistic InfectionFemaleDrug ComplicationSafetymedicine.drugAdultmedicine.medical_specialtyAdolescentIBDOpportunistic InfectionsAntibodies Monoclonal HumanizedYoung AdultInternal medicinemedicineAdalimumab80 and over AntibodieHumansImmunologic FactorsRisk factoradverse effects/therapeutic use Inflammatory Bowel DiseaseAgedHepatologymortality/therapy Male Middle Aged Neoplasmepidemiology Tumor Necrosis Factor-alphabusiness.industryTumor Necrosis Factor-alphaAdalimumabmedicine.diseaseInflammatory Bowel DiseasesCrohn's Disease Activity IndexInfliximabInfliximabSurgeryInflammation Side Effects Drug ComplicationsSide Effectinflammationadverse effects/therapeutic use Female Humans Immunologic FactorAdolescent Adult Age Factors Aged Agedbusiness
researchProduct

Incidence, Clinical Characteristics, and Management of Psoriasis Induced by Anti-TNF Therapy in Patients with Inflammatory Bowel Disease: A Nationwid…

2016

Background: Psoriasis induced by anti-tumor necrosis factor-alpha (TNF) therapy has been described as a paradoxical side effect. Aim: To determine the incidence, clinical characteristics, and management of psoriasis induced by anti-TNF therapy in a large nationwide cohort of inflammatory bowel disease patients. Methods: Patients with inflammatory bowel disease were identified from the Spanish prospectively maintained Estudio Nacional en Enfermedad Inflamatoria Intestinal sobre Determinantes geneticos y Ambientales registry of Grupo Espanol de Trabajo en Enfermedad de Croh y Colitis Ulcerosa. Patients who developed psoriasis by anti-TNF drugs were the cases, whereas patients treated with ant…

MaleAnti-Inflammatory AgentsInflammatory bowel diseaseGastroenterologyCohort Studies030207 dermatology & venereal diseases0302 clinical medicineCrohn DiseaseadalimumabImmunology and AllergyIncidence (epidemiology)IncidenceGastroenterologypsoriasisPrognosisside effectsCrohn's diseaseCohort030211 gastroenterology & hepatologyTumor necrosis factor alphaFemaleCohort studyAdultmedicine.medical_specialtyAdolescent03 medical and health sciencesGastrointestinal Agentsinflammatory bowel diseasePsoriasisInternal medicinemedicineHumansPsoriasisColitisulcerative colitisbusiness.industryTumor Necrosis Factor-alphaCase-control studyAdalimumabanti-TNFmedicine.diseaseInfliximabWithholding TreatmentSpainCase-Control StudiesPhysical therapyColitis UlcerativebusinessinfliximabFollow-Up Studies
researchProduct

Role of meprins to protect ileal mucosa of Crohn's disease patients from colonization by adherent-invasive E. coli

2011

Ileal lesions in Crohn's disease (CD) patients are colonized by pathogenic adherent-invasive Escherichia coli (AIEC) able to adhere to and invade intestinal epithelial cells (IEC), and to survive within macrophages. The interaction of AIEC with IEC depends on bacterial factors mainly type 1 pili, flagella, and outer membrane proteins. In humans, proteases can act as host defence mechanisms to counteract bacterial colonization. The protease meprin, composed of multimeric complexes of the two subunits alpha and beta, is abundantly expressed in IECs. Decreased levels of this protease correlate with the severity of the inflammation in patients with inflammatory bowel disease. The aim of the pre…

MaleBacterial Diseasesmedicine.medical_treatmentACTIVATION MECHANISMBiochemistryBacterial AdhesionPilusMice0302 clinical medicineCrohn DiseaseIntestinal mucosaMolecular Cell BiologyGastrointestinal InfectionsIntestinal MucosaAged 80 and over0303 health sciencesMultidisciplinaryQRMetalloendopeptidasesMiddle AgedEnzymesBacterial Pathogens3. Good healthHost-Pathogen InteractionInfectious DiseasesCytokineESCHERICHIA-COLI030220 oncology & carcinogenesisAlimentation et NutritionMedicineFemaleINFLAMMATORY-BOWEL-DISEASE;INTESTINAL EPITHELIAL-CELLS;URINARY-TRACT-INFECTIONS;ESCHERICHIA-COLI;ALPHA-SUBUNIT;STRAIN LF82;METALLOPROTEASE MEPRIN;ACTIVATION MECHANISM;BETA-SUBUNIT;TYPE-1 PILICellular Typesmedicine.symptomBacterial outer membraneALPHA-SUBUNITResearch ArticleAdultProteasesScienceMédecine humaine et pathologieInflammationGastroenterology and HepatologyBiologyMETALLOPROTEASE MEPRINMicrobiologyMicrobiologyURINARY-TRACT-INFECTIONS03 medical and health sciencesTYPE-1 PILIEscherichia colimedicineAnimalsHumansFood and NutritionSecretionInterleukin 8BETA-SUBUNITBiologyAged030304 developmental biologySTRAIN LF82Interleukin-8Inflammatory Bowel DiseaseEpithelial Cellsdigestive system diseasesMice Inbred C57BLHuman health and pathologyINTESTINAL EPITHELIAL-CELLS[SDV.AEN]Life Sciences [q-bio]/Food and Nutrition[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyINFLAMMATORY-BOWEL-DISEASE
researchProduct

Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept

2016

Background: Data from routine clinical practice are needed to further define the efficacy and safety of biologic medications in children with juvenile idiopathic arthritis (JIA). The aim of this analysis was to investigate the disease status, reasons for discontinuation and adverse events in Italian JIA patients treated with etanercept (ETN). Methods: In 2013, all centers of the Italian Pediatric Rheumatology Study Group were asked to make a census of patients given ETN after January 2000. Patients were classified in three groups: group 1 = patients still taking ETN; group 2 = patients discontinued from ETN for any reasons; group 3 = patients lost to follow-up while receiving ETN. All three…

MaleBiologic therapieBiologic therapies; Etanercept; Juvenile idiopathic arthritis; Pediatric rheumatology; TNF inhibitors; Adolescent; Antirheumatic Agents; Arthritis Juvenile; Child; Child Preschool; Cross-Sectional Studies; Drug Substitution; Etanercept; Female; Humans; Male; Methotrexate; Patient Outcome Assessment; Retrospective Studies; Treatment Outcome; Pediatrics Perinatology and Child Health; Rheumatology; Immunology and AllergyArthritisJuvenilePediatricsInflammatory bowel diseaseEtanerceptEtanerceptTNF inhibitorsSettore MED/38 - Pediatria Generale E Specialistica0302 clinical medicineQuality of lifeRetrospective StudieImmunology and AllergyPediatric rheumatology030212 general & internal medicineChildBiologic therapies; Etanercept; Juvenile idiopathic arthritis; Pediatric rheumatology; TNF inhibitors; Pediatrics Perinatology and Child Health; Immunology and Allergy; RheumatologyDrug SubstitutionBiologic therapies; Etanercept; Juvenile idiopathic arthritis; Pediatric rheumatology; TNF inhibitors; Adolescent; Antirheumatic Agents; Arthritis Juvenile; Child; Child Preschool; Cross-Sectional Studies; Drug Substitution; Etanercept; Female; Humans; Male; Methotrexate; Patient Outcome Assessment; Retrospective Studies; Treatment Outcome; Pediatrics Perinatology and Child Health; Immunology and Allergy; RheumatologyAntirheumatic AgentPerinatology and Child Health3. Good healthTreatment OutcomeSettore MED/38 - PEDIATRIA GENERALE E SPECIALISTICAChild PreschoolAntirheumatic AgentsFemaleResearch ArticleHumanmedicine.drugBiologic therapies; Etanercept; Juvenile idiopathic arthritis; Pediatric rheumatology; TNF inhibitors; Adolescent; Antirheumatic Agents; Arthritis Juvenile; Child; Child Preschool; Cross-Sectional Studies; Drug Substitution; Etanercept; Female; Humans; Male; Methotrexate; Patient Outcome Assessment; Retrospective Studies; Treatment Outcomemedicine.medical_specialtyAdolescent03 medical and health sciencesJuvenile idiopathic arthritiRheumatologyInternal medicineBiologic therapies; Etanercept; Juvenile idiopathic arthritis; Pediatric rheumatology; TNF inhibitorsmedicineHumansPediatrics Perinatology and Child HealthAdverse effectPreschoolRetrospective StudiesCross-Sectional Studie030203 arthritis & rheumatologybusiness.industryArthritisRetrospective cohort studyJuvenile idiopathic arthritismedicine.diseaseArthritis JuvenileRheumatologyDiscontinuationPatient Outcome AssessmentBiologic therapiesCross-Sectional StudiesMethotrexatePediatrics Perinatology and Child HealthPhysical therapybusinessTNF inhibitor
researchProduct

New intramedullary locking nail for olecranon fracture fixation--an in vitro biomechanical comparison with tension band wiring.

2010

The aim of this study was to determine the difference in displacement of a newly designed intramedullary olecranon fracture fixation device compared with multifilament tension band wiring after 4 cycles and 300 cycles of dynamic continuous loading.In eight pairs of fresh-frozen cadaver ulnae, oblique olecranon fractures were created and stabilized using either newly designed intramedullary olecranon nail or multifilament tension band wiring. The specimens were then subjected to continuous dynamic loading (from 25 N to 200 N) using matched pairs of cadaveric upper extremities. The Wilcoxon test was used to determine statistical differences of the displacement in the fracture gap.After 4 cycl…

MaleBone NailsCritical Care and Intensive Care MedicineProsthesis Designlaw.inventionIntramedullary rodFixation (surgical)lawFracture fixationElbow JointmedicineHumansDisplacement (orthopedic surgery)Olecranon ProcessRange of Motion ArticularBone WiresAgedOrthodonticsAged 80 and overbusiness.industryTension band wiringMiddle Agedmedicine.diseaseUlna FracturesBiomechanical PhenomenaFracture Fixation Intramedullarymedicine.anatomical_structureOlecranon fractureNail (anatomy)SurgeryFemaleStress MechanicalbusinessElbow InjuriesBone WiresThe Journal of trauma
researchProduct

Colonic stenting in acutely obstructed left-sided colon cancer Clinical evaluation and cost analysis.

2015

This retrospective study aims to evaluate clinical and cost effectiveness of colonic stenting as a bridge to surgery and as a palliative treatment in acutely obstructed left-sided colon cancer.Onehundred fortyfour patients were collected between 2006 and 2012, with acute left-sided malignant colonic obstruction with no evidence of peritonitis: 96 patients underwent surgical treatment, 48 underwent decompressive stenting. For the stenting we used self-expandable metallic stent in nitinol.Patients who had successful colonic stenting were 40, 8 underwent elective surgery within 10 days, 32 decompression stenting had only palliative intent. in 8/48 patients subjected to stenting decompression t…

MaleBowel obstruction Colonic cancer Colonic stenting.Palliative CareSettore MED/18 - Chirurgia GeneraleTreatment OutcomeItalyColonic NeoplasmsCosts and Cost AnalysisHumansFemaleStentsColectomyIntestinal ObstructionFollow-Up StudiesRetrospective Studies
researchProduct

Ileal Melanoma, A Rare Cause of Small Bowel Obstruction: Report of a Case, and Short Literature Review.

2020

Background: Malignant melanoma frequently spreads to the gastrointestinal tract, with 60% of patients with advanced metastatic disease showing digestive involvement; however, primary MM of the small intestine is a controversial diagnosis. In fact, whether these lesions arise as true small bowel primary neoplasms or represent metastases from unidentified cutaneous melanomas remains debatable. The most common complications are intestinal obstruction, massive gastrointestinal bleeding, and perforation. Objective & Methods: We report a case of a 64-year-old patient, with an unremarkable medical history, in which a late diagnosis of primary ileal malignant melanoma in the setting of an emer…

MaleCT scanmedicine.medical_specialtyGastrointestinal bleedingmedicine.medical_treatmentPerforation (oil well)Metastasis03 medical and health sciences0302 clinical medicineIleumLaparotomymedicineHumansRadiology Nuclear Medicine and imagingMedical historymetastatic disease.Ileal MelanomaSmall Bowel ObstructionAntineoplastic Agents AlkylatingMelanomaPharmacologyGastrointestinal tractCurrent Radiopharmaceuticalsbusiness.industryGeneral surgeryMelanomaMiddle Agedmedicine.diseaseBowel obstructionDacarbazineIleal NeoplasmsSettore MED/18 - Chirurgia GeneralePEThypercaptation030220 oncology & carcinogenesisPositron-Emission Tomography030211 gastroenterology & hepatologybusinessmetastatic diseaseIntestinal ObstructionCurrent radiopharmaceuticals
researchProduct